Real-Time Blood Glucose Continuous Glucose Monitoring (CGM) Patch Global Market Report 2025

The real-time blood glucose continuous glucose monitoring (CGM) patch market size has grown rapidly in recent years. It will grow from $6.12 billion in 2024 to $7.04 billion in 2025 at a compound annual growth rate (CAGR) of 15%. The growth during the historic period can be attributed to broader reimbursement coverage, a strong clinical evidence base, clinician training and familiarity, a shift toward home-based chronic care, and endorsement in professional guidelines.

The real-time blood glucose continuous glucose monitoring (CGM) patch market size is expected to see rapid growth in the next few years. It will grow to $12.14 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth during the forecast period can be attributed to increasing prediabetes screening and earlier diagnosis, expanded coverage for insulin and non-insulin users, value-based care incentives linked to time in range outcomes, aging populations with higher metabolic disease burden, and urbanization and dietary transitions in emerging economies. Key trends in the forecast period include extended-wear patch sensors beyond two weeks, integration of automated insulin delivery with patch-based continuous glucose monitoring, direct-to-watch connectivity without relying on smartphones, on-body vibration and discreet alert innovations, and advanced biocompatible adhesives that reduce skin irritation.

The rising prevalence of diabetes is expected to drive the growth of the real-time blood glucose continuous glucose monitoring (CGM) patch market. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels due to insufficient insulin production or insulin resistance. Its prevalence is increasing as rising obesity rates lead to higher insulin resistance, disrupting blood sugar regulation and significantly increasing the risk of developing type 2 diabetes. Real-time blood glucose CGM patches enable people with diabetes to continuously monitor glucose levels, providing timely alerts for hyperglycemia or hypoglycemia, supporting informed dietary, medication, and lifestyle decisions, and improving overall disease management while reducing complication risks. For example, in June 2024, the National Health Service in the UK reported that in 2023, over 549,000 additional individuals in England were identified at risk of type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia or prediabetes registered with a GP to 3,615,330, up nearly 20% from 3,065,825 in 2022. This demonstrates how the rising prevalence of diabetes is driving market growth.

Key companies in the real-time blood glucose CGM patch market are focusing on innovative products such as over-the-counter continuous glucose monitoring sensors to increase access and convenience. Over-the-counter CGM sensors are wearable devices that track glucose levels in real time without a prescription, enabling users to continuously monitor glucose, understand lifestyle impacts, and manage or prevent diabetes more easily. For instance, in September 2024, Dexcom Inc., a US-based diabetes technology company, launched Stelo, its first OTC CGM patch in the United States. The small, wearable sensor attaches to the back of the upper arm and provides real-time glucose readings directly to a smartphone app without fingersticks. Designed for people with type 2 diabetes not using insulin and those with prediabetes, Stelo delivers personalized insights on how diet, exercise, and sleep affect glucose levels. The device offers up to 15-day wear, waterproofing, spike and pattern detection, and integrates with Dexcom’s glucose sensing technology, making continuous glucose monitoring more accessible and actionable for a wider population.

In January 2024, Trinity Biotech plc, an Ireland-based diagnostics company, acquired the biosensor and CGM assets of Waveform Technologies Inc. for $12.5 million in cash and 9 million ADSs. This acquisition enables Trinity Biotech to enter the growing biosensor and CGM market by leveraging Waveform’s needle-free CGM technology to develop next-generation wearable biosensors, target additional biomarkers, and promote broader global adoption of affordable diabetes care tools. Waveform Technologies Inc. is a US-based company specializing in real-time blood glucose CGM patch technology.

Major players in the real-time blood glucose continuous glucose monitoring (CGM) patch market are F. Hoffmann-La Roche AG, Abbott Laboratories, Medtronic plc, Dexcom Inc., Trinity Biotech plc, Biolinq Inc., Ascensia Diabetes Care Holdings AG, Senseonics Holdings Inc., A. Menarini Diagnostics S.r.l., RSP Systems A/S, OrSense Ltd., Rockley Photonics Holdings Ltd., Sinocare Inc., CNOGA Medical Ltd., Medtrum Technologies Inc., Nutromics Ltd., Nemaura Medical Inc., DiaMonTech GmbH, Movano Health Inc., and GlucoRx Ltd.

North America was the largest region in the real-time blood glucose continuous glucose monitoring (CGM) patch market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in real-time blood glucose continuous glucose monitoring (CGM) patch report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The real-time blood glucose continuous glucose monitoring (CGM) patch market research report is one of a series of new reports that provides real-time blood glucose continuous glucose monitoring (CGM) patch market statistics, including real-time blood glucose continuous glucose monitoring (CGM) patch industry global market size, regional shares, competitors with the real-time blood glucose continuous glucose monitoring (CGM) patch market share, real-time blood glucose continuous glucose monitoring (CGM) patch market segments, market trends, and opportunities, and any further data you may need to thrive in the real-time blood glucose continuous glucose monitoring (CGM) patch industry. This real-time blood glucose continuous glucose monitoring (CGM) patch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A real-time blood glucose continuous glucose monitoring (CGM) patch is a wearable device that continuously monitors glucose levels in the interstitial fluid beneath the skin. It transmits glucose readings in real time to a connected display or mobile device, enabling continuous tracking of glucose trends. The patch functions through a small sensor and transmitter that provide frequent data updates without requiring fingerstick measurements.

The primary product types of real-time blood glucose continuous glucose monitoring (CGM) patches are wearable CGM patches and implantable CGM patches. A wearable CGM patch is a discreet, skin-worn sensor that continuously tracks glucose levels and transmits real-time data to support management of diet, activity, and medication. These patches incorporate various technologies, including enzymatic and non-enzymatic systems, and are distributed through channels such as online pharmacies, retail pharmacies, hospital pharmacies, and other outlets. They are used for applications including type 1 diabetes, type 2 diabetes, gestational diabetes, and other conditions, and are utilized by hospitals, clinics, homecare settings, diagnostic centers, and other end-users.

The countries covered in the real-time blood glucose continuous glucose monitoring (CGM) patch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The real-time blood glucose continuous glucose monitoring (CGM) patch market consists of revenues earned by entities by providing services such as remote patient monitoring and telehealth support, subscription and replacement programs, distribution and logistics management, clinical and diagnostic glucose monitoring services, research and development for sensor innovation, customer training and technical support, and reimbursement or healthcare partnership services. The market value includes the value of related goods sold by the service provider or included within the service offering. The real-time blood glucose continuous glucose monitoring (CGM) patch market also includes sales of microneedles paper-type biodegradable sensor, disposable patch sensor, and adhesive-backed sensor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.